Drug Information

   


  











Pharmacokinetics




Ethosuximide is readily absorbed from the gastrointestinal tract and
extensively hydroxylated in the liver to its principal metabolite which
is reported to be inactive. It is excreted in the urine mainly in the
form of its metabolites either free or in conjugated form but about 20%
is also excreted as unchanged ethosuximide.

Ethosuximide is
widely distributed throughout the body, but is not significantly bound
to plasma proteins. A half-life of about 60 hours has been reported for
adults with a shorter half-life of about 30 hours in children.

Monitoring of
plasma concentrations has been suggested as an aid in assessing control
and the therapeutic range of ethosuximide is usually quoted as being 40
to 100 micrograms per mL (about 300 to 700 micromol per litre);
measurement of concentrations in saliva and tears has also been
performed.x

Ethosuximide crosses the
placental barrier, and is distributed into breast milk.

Top

   




Indication & Dosage




In Combination with other anticonvulsants when other forms of epilepsy
coexist with petitmal, Petit mal Epilepsy.

Dosage: Adults: 500mg daily, increased gradually to 1-1.5g daily.

Children: Upto 6 years: Intially 250mg daily, increased gradually
tousual dose of 20mg/kg daily.Above 6 year: Same as adult dose.

Top

   

Action

Both isoniazid and valproic acid may 
the effects of ethosuximide.

Top

   



Interactions



Hydantoins: Serum hydantoin levels may be increased.

Primidone: Serum levels of Cabamazepine: Increased. 

Carbamazepine: Increases clearance of ethosuximide

Sodium valproate: Increases plams ethosuximede levels.

Alcohol: Enhances sedative effect.

Isoniazid: Increases plasma concentration of ethosuximide, risk of
toxicity.

Antidepressants: Antagonism, convulsive threshold decreased.

Antipsychotics: Antagonism, conculsive threshold decreased.

Top

   



Adverse
Effect & Precautions




Dizziness, headache, confusion, ataxia, anorexia, nausea, epigastric
distress and lack of concentration. Skin rash, neutropenia and aplastic
anaemia may occur.



Precaution: It should be avoided in hepatic or renal disease. Periodic
blood count should be done. Abrupt withdrawal.

Pregnancy: Use with caution.

Breast Feeding: Use with caution.

Man: May be given in reduced dose.

Top

   







ZARONTIN
Parke-Davis
Ethosuximide
50mg/ml; syrup Absence(petit mal) Seizures.
114ml 38.95



Top

  






 

  

   
Drug Information
   

  

Pharmacokinetics

Ethosuximide is readily absorbed from the gastrointestinal tract and extensively hydroxylated in the liver to its principal metabolite which is reported to be inactive. It is excreted in the urine mainly in the form of its metabolites either free or in conjugated form but about 20% is also excreted as unchanged ethosuximide.

Ethosuximide is widely distributed throughout the body, but is not significantly bound to plasma proteins. A half-life of about 60 hours has been reported for adults with a shorter half-life of about 30 hours in children.

Monitoring of plasma concentrations has been suggested as an aid in assessing control and the therapeutic range of ethosuximide is usually quoted as being 40 to 100 micrograms per mL (about 300 to 700 micromol per litre); measurement of concentrations in saliva and tears has also been performed.x

Ethosuximide crosses the placental barrier, and is distributed into breast milk.

Top
   

Indication & Dosage

In Combination with other anticonvulsants when other forms of epilepsy coexist with petitmal, Petit mal Epilepsy.
Dosage: Adults: 500mg daily, increased gradually to 1-1.5g daily.
Children: Upto 6 years: Intially 250mg daily, increased gradually tousual dose of 20mg/kg daily.Above 6 year: Same as adult dose.

Top
   

Action

Both isoniazid and valproic acid may  the effects of ethosuximide.

Top
   

Interactions

Hydantoins: Serum hydantoin levels may be increased.
Primidone: Serum levels of Cabamazepine: Increased. 
Carbamazepine: Increases clearance of ethosuximide
Sodium valproate: Increases plams ethosuximede levels.
Alcohol: Enhances sedative effect.
Isoniazid: Increases plasma concentration of ethosuximide, risk of toxicity.
Antidepressants: Antagonism, convulsive threshold decreased.
Antipsychotics: Antagonism, conculsive threshold decreased.

Top
   

Adverse Effect & Precautions

Dizziness, headache, confusion, ataxia, anorexia, nausea, epigastric distress and lack of concentration. Skin rash, neutropenia and aplastic anaemia may occur.

Precaution: It should be avoided in hepatic or renal disease. Periodic blood count should be done. Abrupt withdrawal.
Pregnancy: Use with caution.
Breast Feeding: Use with caution.
Man: May be given in reduced dose.

Top
   

ZARONTIN

Parke-Davis

Ethosuximide 50mg/ml; syrup Absence(petit mal) Seizures.

114ml

38.95

Top
  

 

By |2022-07-20T16:43:01+00:00July 20, 2022|Uncategorized|Comments Off on Ethosuximide

About the Author: